Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of Change in CYP3A Activity by Route of Administration Using Metabolic Markers
NCT03366974Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of midazolam, sponsored by Seoul National University Hospital. Primary endpoints: Area under the curve of midazolam (AUClast), Metabolic ratio of steroids and 1 more. Started Dec 2017; status: completed.
02
Drugs
midazolam
Beyond the preview
Go deeper on NCT03366974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366974.